Every day throughout the world, physicians, nurses, and an array of other health professionals use a stethoscope, which was invented by René Laennec in 1816 ([@b164-ehp-118-1515]). It is a relatively simple instrument whose sounds can indicate a myriad of disease states that can then be confirmed by more sophisticated assessments. It is hard to visualize a physician or imagine medicine without the stethoscope. Similarly, the *Salmonella* mutagenicity assay, which was developed initially as a spot test ([@b2-ehp-118-1515]), then as a plate-incorporation test ([@b5-ehp-118-1515]) using strains of *Salmonella* bacteria derived from studies by B.N. Ames and P.E. Hartman ([@b66-ehp-118-1515]) and rodent liver microsomal activation coupled initially to the assay by H.V. Malling ([@b109-ehp-118-1515]), is a deceptively simple tool that can be used to detect the mutagenicity of environmental chemicals, environmental mixtures, body fluids, foods, drugs, and physical agents. More complex tests can be applied to confirm and characterize further the mutagenic activity of the agent. Although neither the stethoscope nor the *Salmonella* assay provides a definitive diagnosis/detection of a disease or a mutagen, respectively, both are indispensible first-line tools in their fields.

There is much unrest in the field of toxicology today because of a variety of scientific developments, including advances in genomic science ([@b127-ehp-118-1515]; [@b169-ehp-118-1515]), improved knowledge of the molecular and mechanistic basis for biological responses to toxicant exposure ([@b62-ehp-118-1515]), legislation mandating reduced numbers of animals for toxicology testing ([@b129-ehp-118-1515]), and governmental direction to incorporate all of the above into a new paradigm for toxicology for the 21st century ([@b123-ehp-118-1515]).

A strict parallel cannot be drawn between a targeted testing assay such as the *Salmonella* assay, which is used for hazard identification, and a high-throughput screening (HTS) assay such as either the ToxCast program \[U.S. Environmental Protection Agency (EPA)\] or the combined U.S. EPA/National Institutes of Health (NIH)/National Institute of Environmental Health Sciences (NIEHS)/National Toxicology Program (NTP) Tox21 program ([@b89-ehp-118-1515]), which can identify specific signaling or biochemical pathways relevant to potential disease development and thus have the possibility of going beyond hazard identification. An assay like the *Salmonella* assay is a stand-alone screen that requires high accuracy and reproducibility and is correlated with health end points, permitting its use for regulatory purposes. In contrast, HTS assays use emerging technologies and target probes, knowledge of biochemical and disease pathways in rodents and humans, genomics, and other technologies to generate a profile or pattern of effects across a range of chemical classes and biological end points that do not depend greatly on any particular chemical or assay result. As with the *Salmonella* assay, HTS assays are viewed as a first-line screening tool, with results of interest being followed up by more extensive confirmatory assays.

In the process of developing and adopting new methods, it is important to build on and learn from past paradigm shifts, several of which occurred in the field of genetic toxicology with the introduction of the *Salmonella* assay. Consequently, the history of the *Salmonella* assay highlights some of the necessary steps and considerations needed for the development of almost any type of toxicology assay, including some aspects of HTS assays. Our purpose with this review is to *a*) describe the paradigm shifts precipitated by the *Salmonella* assay, including the demonstration of a connection between mutagenicity and carcinogenicity and the ubiquitous nature of mutagens in our environment; *b*) document the historic and current applications of the *Salmonella* assay; and *c*) illustrate the lessons learned from the development, validation, testing, assessment, and uses of this *in vitro* assay that may be applicable to the development of *in vitro* toxicology assays for the 21st century.

Paradigm Shift I: Relating Mutagenic Activity to Carcinogenic Activity
======================================================================

By the middle of the 20th century, there was almost no evidence to support a role for mutation in cancer, and few carcinogens were known to be mutagens ([@b26-ehp-118-1515]). However, at this time efforts began to screen carcinogens and other chemicals for mutagenicity *in vitro*, starting with the use of a base-substitution strain of *Escherichia coli* by [@b43-ehp-118-1515] and then by [@b149-ehp-118-1515], who assessed \> 400 compounds using filter-paper disks in a spot test with the same strain. This concept was expanded by the development of a set of tester strains that detected different types of gene mutations in *Salmonella typhimurium* ([@b167-ehp-118-1515]) and in the fungus *Neurospora crassa* ([@b107-ehp-118-1515]). Many *in vitro* mutagenicity assays were developed throughout this period, including the *ad-3* forward-mutation assay in *N. crassa* ([@b45-ehp-118-1515]); cytogenetic assays ([@b91-ehp-118-1515]); *Hprt* (hypoxanthine-guanine phosphoribosyltransferase) assays in V79 ([@b31-ehp-118-1515]) and CHO cells ([@b79-ehp-118-1515]); the *Tk^+/−^* (thymidine kinase) assay in mouse lymphoma cells ([@b40-ehp-118-1515]); and assays in yeast ([@b177-ehp-118-1515]). The development of these and subsequent assays in mammalian cells and *in vivo* was predicated on the notion that mutagenicity results in these systems would be more relevant to humans than would those from bacteria.

Despite concerted efforts, few mutagens beyond direct-acting alkylating agents were discovered initially with these assays, and known rodent carcinogens other than direct-acting alkylating agents were largely negative in these assays. However, as reviewed by [@b25-ehp-118-1515], a paradigm shift began when [@b108-ehp-118-1515] used a hydroxylating mixture to activate diethyl- and dimethylnitrosamine, which were not mutagenic *in vitro*, to metabolites that were mutagenic in *N. crassa*. Building on this observation, as well as on the work of [@b119-ehp-118-1515] and in consultation with H. Gelboin at NIH/NCI, [@b109-ehp-118-1515] then coupled the *Salmonella* mutagenicity assay with *in vitro* metabolic activation composed of the supernatant from mouse liver homogenate centrifuged at 30,000 × *g* (microsomes) plus cofactors. Using this microsomal activation mixture, [@b109-ehp-118-1515] showed that dimethylnitrosamine was mutagenic in *Salmonella* in a liquid-suspension assay, resulting in the first version of what would later be called the *Salmonella*/mammalian microsome mutagenicity assay. The host-mediated assay provided additional evidence that carcinogens could be mutagens after mammalian metabolism ([@b100-ehp-118-1515]). [@b5-ehp-118-1515] then showed that DNA-reactive metabolites of known carcinogens were mutagenic (no metabolic activation was used); in that paper, the authors also introduced the plate-incorporation version of the assay, where the bacteria and chemical were combined in the top agar on the Petri plate.

The connection between mutagenesis and carcinogenesis developed further when [@b4-ehp-118-1515] combined their *Salmonella* tester strains, the test chemical, and the supernatant from a 9,000 × *g* centrifugation of rat liver homogenate (S9 fraction) along with cofactors, as described by [@b56-ehp-118-1515], together in the top agar and showed that a variety of heretofore nonmutagenic rodent carcinogens were, in fact, mutagenic after metabolic activation. This plate-incorporation version of the *Salmonella*/mammalian microsome mutagenicity assay became a standard that is still in use today. Various modifications, including reduced nucleotide-excision repair, enhanced cell-wall permeability ([@b6-ehp-118-1515]), and enhanced error-prone repair achieved by the introduction of a plasmid \[as suggested by [@b105-ehp-118-1515]\], combined to make for a highly sensitive test system ([@b112-ehp-118-1515]). Consequently, a new paradigm emerged within just a few years that led to an entirely new approach to carcinogen prediction and testing. This spurred the use of *in vitro* assays for mutagenicity in bacteria and mammalian cells as predictors of potential rodent and human carcinogens ([@b152-ehp-118-1515]), culminating in the current genetic toxicity test battery ([@b50-ehp-118-1515]).

Decades of research have shown that mutagenesis is a critical component of carcinogenesis, based on a range of evidence including mutation spectra ([@b47-ehp-118-1515]; [@b64-ehp-118-1515]) and genomic sequencing of tumors ([@b169-ehp-118-1515]; [@b127-ehp-118-1515]). Thus, now it is difficult to recall that once it was somewhat bold to propose that there was any direct connection between the two processes ([@b97-ehp-118-1515]; [@b119-ehp-118-1515]). Prior to 1972, it was not yet clear that the electrophilicity of some chemical carcinogens had a necessary role in the potential mutagenic activity of such compounds or even that DNA, as opposed to protein, was the ultimate target of carcinogens ([@b120-ehp-118-1515]).

Although sound theoretical reasons existed for proposing that carcinogens might act through a mutagenic mechanism, a compelling demonstration of this connection did not yet exist ([@b119-ehp-118-1515]). In fact, mutagenesis shared the stage with other likely mechanisms, including epigenetic changes ([@b120-ehp-118-1515]; [@b119-ehp-118-1515]), altered expression of an integrated viral genome ([@b155-ehp-118-1515]), or alteration of immunological factors by carcinogens, permitting the formation and growth of tumors ([@b17-ehp-118-1515]). Of course, time has shown that all of the above mechanisms are important, especially epigenetic mechanisms ([@b84-ehp-118-1515]), which may be particularly relevant for nonmutagenic carcinogens. Given the much broader range of biology that future assays will detect, new paradigm shifts will emerge in other areas of toxicology from 21st century assays.

Paradigm Shift II: Recognition of Ubiquitous Mutagenic Activity in the Environment
==================================================================================

When [@b2-ehp-118-1515] first introduced the assay, he stated "I will be glad to mail the strains to people desiring them and to serve as a clearinghouse for new and improved bacterial tester strains." Consequently, by the late 1970s, \> 2,000 laboratories around the world had requested the *Salmonella* tester strains to initiate studies in environmental mutagenesis ([@b3-ehp-118-1515]). The fact that neither Ames nor his employer (University of California-Berkeley) patented the strains and that he made them freely available facilitated their use and dissemination throughout academic, industrial, and government laboratories worldwide---promoting the development of many creative uses and modifications of the assay. Creative uses may also emerge from 21st century assays, especially those developed in the public sector, which would have some probability of being disseminated freely.

The initial uses of the *Salmonella* assay led to the startling (at the time) recognition that our environment is replete with mutagens, including fungal toxins, combustion emissions, industrial chemicals, and drugs. The *Salmonella* assay was essential to this effort, providing the means by which researchers discovered for the first time that much of our environment had mutagenic activity, including cigarette smoke ([@b90-ehp-118-1515]), urban air ([@b150-ehp-118-1515]; [@b154-ehp-118-1515]), river water ([@b128-ehp-118-1515]), drinking water ([@b104-ehp-118-1515]), food ([@b148-ehp-118-1515]), and soil ([@b59-ehp-118-1515]). The assay was used to show that even people could have systemic mutagenic activity detectable in urine after smoking ([@b170-ehp-118-1515]) or after eating fried meat ([@b16-ehp-118-1515]). Decades of studies have shown that nearly all urban air samples tested ([@b36-ehp-118-1515]; [@b39-ehp-118-1515]), drinking water ([@b140-ehp-118-1515]), soil ([@b166-ehp-118-1515]), and house dust ([@b106-ehp-118-1515]) are mutagenic. These reviews document that at least 40--50% of the papers published thus far on the genotoxicity of, for example, air, soil, water, and house dust have used the *Salmonella* assay, and they show that the vast majority of contemporary studies rely almost exclusively on the *Salmonella* assay for mutagenicity assessments of environmental media.

The realization that much of the environment had mutagenic activity was unanticipated by most researchers and posed a challenge to environmental scientists, public health authorities, and regulators. As 21st century toxicology proceeds, previously unrecognized, ubiquitous toxicities in our environment may be discovered---beyond findings of mutagenicity and potential carcinogenicity---and a new paradigm of toxicity effects may emerge ([@b22-ehp-118-1515]). Regulators and public health authorities may have to expand or reconsider their approaches based on the results from such assays.

How the *Salmonella* Assay Has Been Used
========================================

Published data
--------------

We searched three publication databases \[PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>), Scopus (<http://www.scopus.com/home.url>), and Web of Knowledge (<http://apps.isiknowledge.com/>)\], and we found 10,169 unique publications dealing with the *Salmonella* assay. This was accomplished by searching each database for "Ames test OR *Salmonella* mutagen." This gave 11,064 responses in PubMed, 13,694 in Scopus, and 3,453 in the Web of Knowledge. Although it is likely that not all references were found in this search, the number of references retrieved should give a good sampling of trends. We merged the citations into an EndNote (Thomson Reuters, New York, NY) database, and we deleted duplicates based on the same first author name, journal name, journal year, volume, and page number. We examined the remaining information individually to eliminate additional duplicates, non-*Salmonella* mutagenicity papers, abstracts, and papers that seemed to refer to the assay only tangentially. Then we categorized papers by key words/phrases that reflected how the assay was used or discussed within the context of the paper. The final database had 10,169 publications sorted into 7 major categories and 20 subcategories. A publication was often included in more than one category/subcategory based on the nature of that publication. The reference database is available in Supplemental Material (doi:10.1289/ehp.1002336).

[Figure 1A](#f1-ehp-118-1515){ref-type="fig"} shows the numbers of publications per year that have used the *Salmonella* assay as well as the other gene-mutation assays developed near the same time, including those in mammalian cells. The number of publications using the *Salmonella* assay rose dramatically, peaking at approximately 500 papers/year in the early 1980s, but has declined gradually to a rather constant level of approximately 200 papers/year during the past decade. Other assays rose to approximately 10--20 papers/year, with the mouse lymphoma *Tk^+/−^* assay remaining at that level today.

Subsequently, newer genotoxicity assays became popular, and the number of publications for these are shown in [Figure 1B](#f1-ehp-118-1515){ref-type="fig"}. By far, the comet assay has the highest surge in usage and is just now starting to plateau. The micronucleus assays also are prominent, with approximately 100 papers/year being published consistently for the past 20 years. The publication frequency for papers using micronucleus assays has surpassed those using *in vitro* chromosome aberration assays, which peaked in the mid-1980s (data not shown).

With regard to the *Salmonella* assay, the papers documenting the testing of agents associated with environmental samples ([Figure 1C](#f1-ehp-118-1515){ref-type="fig"}), as well as commerce, metabolism, or personal exposure ([Figure 1D](#f1-ehp-118-1515){ref-type="fig"}), peaked in the 1980s but still continue at a steady rate. A closer look at the number of papers published on various types of environmental samples ([Figure 1C](#f1-ehp-118-1515){ref-type="fig"}) shows that *a*) relatively few publications have been associated with soil and sediment samples; *b*) papers looking at air samples follow the overall declining trend seen since 1983; and *c*) publications dealing with water reached a plateau starting in 1980 and have remained stable. However, reports dealing with natural substances have increased since the mid-1990s. This increase is due largely to a search for and analysis of antimutagens, mainly from plant extracts. [Figure 1D](#f1-ehp-118-1515){ref-type="fig"} shows a decline in the number of publications on mechanism and metabolism; although there was a rise in the personal-exposures subcategories until the late 1980s ([Figure 1D](#f1-ehp-118-1515){ref-type="fig"}), the number has since declined.

Unpublished data
----------------

For a variety of reasons, little toxicological data have either been generated or are available publically for a large proportion of compounds in commercial use. For example, toxicological data are available for only 7% of high-production-volume chemicals (\> 1 million pounds/year) ([@b61-ehp-118-1515]) and for only a fraction of regulated industrial chemicals ([@b144-ehp-118-1515]; [@b168-ehp-118-1515]). The few publications dealing with commercial substances ([Figure 1D](#f1-ehp-118-1515){ref-type="fig"}) likely reflect the fact that such data are proprietary. In the U.S. EPA New Chemicals Program, approximately 50,000 premanufacturing notice (PMN) cases have been received since 1979 when the program began; however, only 10% (4,997) have mutagenicity data, with 87% of these (4,351) having *Salmonella* assay data (Cimino MC, personal communication). Thus, only 8.7% of the 50,000 PMNs submitted during the past 30 years have *Salmonella* mutagenicity data, almost none of which are available publically, and approximately 2% of pre-1979 PMNs have been reviewed for the need for toxicological data ([@b61-ehp-118-1515]).

To estimate the percentage of commercial chemicals that are mutagens, [@b175-ehp-118-1515] assembled randomly 100 chemicals in commercial use, which included 46 organics in highest production in the United States (inorganic and elemental compounds were not included among the 100 chemicals), and evaluated them for mutagenicity in the *Salmonella* assay. They found that 22% of the total 100 compounds were mutagenic, and 20% of the subset of 46 high-production compounds were mutagenic. In the absence of required testing and reporting ([@b61-ehp-118-1515]; [@b144-ehp-118-1515]), these data are the best estimates available regarding the proportions of mutagens among organic compounds in current commercial use. Improved estimates may emerge after potential changes to the Toxic Substances Control Act (TSCA) ([@b21-ehp-118-1515]; [@b159-ehp-118-1515]; [@b168-ehp-118-1515]).

The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) program does not keep cumulative data for each assay submitted, largely because each submission is usually considered solely on the basis of the information within it (Benz RD, personal communication). It must be assumed, however, that the pharmaceutical industry also has tested thousands of substances in the *Salmonella* assay. In an analysis using the *Physicians' Desk Reference* from 1999 through 2008, [@b146-ehp-118-1515] compiled the mutagenicity of \> 500 marketed drugs, excluding the cytotoxic anti-cancer and antivirals, nucleosides, steroids, and biologicals. He found that approximately 7% (38/525) of these drugs were mutagenic in bacterial assays (data from either *E. coli* or *Salmonella* assays); this small percentage is likely due to the extensive early screening in the *Salmonella* assay to eliminate mutagenic molecules from further development.

There are a few reports of environmental monitoring programs using the *Salmonella* assay, such as the 20-year program on surface-water mutagenicity in Brazil ([@b157-ehp-118-1515]). However, such monitoring is rarely done and almost never reported in the peer-reviewed literature, although the Brazilian data are available online from the [@b29-ehp-118-1515]. Therefore, the large number of agents whose test results in the *Salmonella* assay have been published may not reflect either the equally large---or larger---number of proprietary chemicals tested by the pharmaceutical and chemical industries or environmental monitoring data, which are not published.

The *Salmonella* Assay as a Model for 21st Century Toxicology Assays
====================================================================

Because of its simplicity, cost effectiveness, flexibility, and large validated database, the *Salmonella* assay is an ideal model to consider in the development of equally reliable *in vitro* toxicology assays for the 21st century. The predictivity, specificity, and sensitivity of the *Salmonella* assay have been validated against selected other mutagenicity assays and rodent carcinogenicity data ([@b152-ehp-118-1515]). Likewise, new HTS assays will need to be validated against something ([@b67-ehp-118-1515]), and one possibility is to measure some end points against the *Salmonella* assay ([@b143-ehp-118-1515]). As outlined by [@b173-ehp-118-1515], there are fundamental procedures to consider when developing, validating, and ultimately accepting new assays, and below we highlight some ways in which the *Salmonella* assay serves as a model for this process.

Standard procedures, quality assurance, and statistical assessment
------------------------------------------------------------------

Soon after the introduction and widespread use of the *Salmonella* assay, researchers recognized the need for standardized procedures. Consequently, Ames published methods papers ([@b7-ehp-118-1515]; [@b112-ehp-118-1515]), and the procedures were quickly adopted by the mutagenesis community. Procedures included the use of positive and negative controls, standard procedures for performing the assay, preparation of S9 mix, checking the tester strains for genetic and physiological stability, and evaluating the results statistically ([@b19-ehp-118-1515]; [@b38-ehp-118-1515], [@b32-ehp-118-1515]; [@b92-ehp-118-1515]; [@b110-ehp-118-1515]; [@b117-ehp-118-1515]; [@b147-ehp-118-1515]). Although positive controls and metabolic activation were generally missing from some first-generation HTS assays, these and other issues are being considered and corrected in current and future iterations of the ToxCast and Tox21 assays ([@b67-ehp-118-1515], [@b68-ehp-118-1515]; [@b80-ehp-118-1515]; [@b88-ehp-118-1515]; [@b165-ehp-118-1515]), as well as for toxicogenomic assays ([@b52-ehp-118-1515]). As noted above, even the early versions of the *Salmonella* assay did not incorporate metabolic activation (because it had not yet been developed). Despite these limitations, initial analyses of data from ToxCast Phase 1 have identified those chemicals able to induce oxidative stress as evidenced by Nrf2 activity ([@b113-ehp-118-1515]).

Structure--activity analysis (SAR)
----------------------------------

Data from the *Salmonella* assay were used by [@b8-ehp-118-1515] to identify structural alerts for potential carcinogenicity, providing critical data for the development of computerized structure--activity methods for carcinogenicity prediction ([@b139-ehp-118-1515]). These methods are still used widely within the chemical, pharmaceutical, and regulatory communities ([@b18-ehp-118-1515]). [@b37-ehp-118-1515] examined *Salmonella* assay data in the peer-reviewed literature for individual chemicals, classified the chemicals by an International Union of Pure and Applied Chemistry chemical class scheme, and found that mutagenicity in the *Salmonella* assay was highly predictive of rodent carcinogenicity for some chemical classes, such as aromatic amines, polycyclic aromatic hydrocarbons, and nitroarenes, but was less predictive for others, such as chlorinated organics. [@b12-ehp-118-1515] noted that for 222 chemicals evaluated by the NTP, data from the *Salmonella* assay, combined with structural alerts and a more limited protocol for the rodent cancer bioassay, permitted the detection of trans-species/multiple-site rodent carcinogens, which are likely human carcinogens ([@b11-ehp-118-1515]; [@b151-ehp-118-1515]).

Building on this past success, current efforts still rely on *Salmonella* assay data and are extending the analyses using newly developed computational methods and structural features. For example, [@b65-ehp-118-1515] assembled a benchmark database containing 6,500 chemicals with *Salmonella* assay data along with structural information \[Simplified Molecular Input Line Entry Specifications (SMILES)\] to develop a prediction model that outperforms a variety of commercial predictive tools. [@b171-ehp-118-1515] compiled a group of 2,428 compounds, each of which has structural information and data for six mutagenicity tests, and showed that the percentage of industrial chemicals that were mutagenic was greater than that of chemicals used as drugs or food ingredients. The incorporation of chemical structure into the DSSTox EPA ToxCast continues to grow ([@b76-ehp-118-1515]), and this structural and toxicology database will enable data from HTS assays to be used for SAR as *Salmonella* assay data have been used for decades.

Reproducibility and transferability of the assay across laboratories
--------------------------------------------------------------------

High reproducibility of an assay allows results to be compared not only within the same laboratory over time but also among laboratories. To address this issue, a set of international, collaborative testing programs was established to evaluate the *Salmonella* assay as well as several other mutagenicity assays using coded chemicals from the same lot ([@b9-ehp-118-1515], [@b10-ehp-118-1515]; [@b44-ehp-118-1515]) and standard protocols ([@b48-ehp-118-1515], [@b49-ehp-118-1515]; [@b111-ehp-118-1515]; [@b131-ehp-118-1515]). These comparative studies paved the way for the establishment of standard methods and procedures for selected mutagenicity assays that are still largely in place. A similar international effort was established for the evaluation of standards of complex mixtures in the *Salmonella* assay ([@b34-ehp-118-1515]; [@b102-ehp-118-1515]).

Concurrently, the establishment of the U.S. EPA GENE-TOX program ([@b137-ehp-118-1515]; [@b163-ehp-118-1515]) provided, to our knowledge, the first self-assessment of the literature in any field of toxicology---in this case, genetic toxicology. This enormous effort ([@b162-ehp-118-1515]) involved 196 scientists who critically read all of the papers published on each of 23 assays, resulting in 41 comprehensive, published reviews. The consequence of this effort was that out of nearly 200 assays, the mutagenesis community agreed on the general use of a subset for routine use, including, for example, the protocols, publication requirements, and use of positive and negative controls, much of which is reflected in the current genotoxicity test battery ([@b50-ehp-118-1515]).

As a plethora of new assays emerge over the coming years, a similar self-assessment being organized by the Transatlantic Think Tank of Toxicology ([@b67-ehp-118-1515]) will be invaluable. Just as with the self-assessment by the GENE-TOX program, it will likely result in the acceptance of just a few assays, as well as the establishment of the standards, protocols, interpretation, and publication requirements for those assays, which will provide a test battery that will serve the regulatory community well in the coming years.

Testing
-------

As reviewed by [@b174-ehp-118-1515], many factors led to the initial effort of the U.S. government, in particular, M. Legator at the FDA, to sponsor mutagenicity testing in 1971, followed by numerous contracts in the ensuing years. Ames himself published an extensive testing and validation study early on in which he used his assay to assess the mutagenicity of 300 compounds ([@b116-ehp-118-1515]; [@b115-ehp-118-1515]). This effort was followed soon by other screening studies involving the *Salmonella* and other assays ([@b24-ehp-118-1515]; [@b82-ehp-118-1515]; [@b122-ehp-118-1515]; [@b135-ehp-118-1515]; [@b141-ehp-118-1515]). The NIEHS/NTP mounted the most comprehensive effort in testing, involving the comparison of four mutagenicity assays along with rodent carcinogenicity data ([@b152-ehp-118-1515]). This effort and subsequent analyses ([@b93-ehp-118-1515]; [@b172-ehp-118-1515]) have shown that the *Salmonella* assay alone, in the absence of a test battery, is reasonably predictive of rodent carcinogenicity. Among a group of chemicals of mixed chemical class, a greater percentage of the compounds that are mutagenic in the *Salmonella* assay are likely to be rodent carcinogens compared with the percentage of nonmutagens likely to be noncarcinogens ([@b93-ehp-118-1515]; [@b172-ehp-118-1515]). At present, there are no reliable methods to assess *Salmonella*-negative compounds for potential carcinogenicity. This conclusion has prompted discussion, pro and con, regarding the option of eliminating the mammalian cell assays from the genotoxicity test battery or the inclusion of other assays ([@b51-ehp-118-1515]; [@b94-ehp-118-1515]).

This development is ironic, as efforts proceed swiftly to develop high-throughput assays in mammalian cells ([@b88-ehp-118-1515]; [@b165-ehp-118-1515]). Despite the theoretical and scientific relevance of mammalian cell assays, their prognostic value may, in fact, be limited. For example, the *Salmonella* assay is less susceptible than mammalian cell assays to artifacts resulting from high toxicity, pH shifts, and osmotic effects ([@b94-ehp-118-1515]). Nonetheless, [@b176-ehp-118-1515] showed that using HTS cell viability data for 1,408 compounds greatly improved quantitative structure--activity relationship (QSAR) predictions for rodent carcinogenicity. They suggest that an approach using improved models, coupled with HTS assay data and structural features of the compounds, might partially replace *in vivo* toxicity testing. Even some *in vivo* assays may be of little or no added value, as indicated by the inability of the mouse bone-marrow micronucleus assay to improve carcinogen prediction beyond that of the *Salmonella* assay alone ([@b172-ehp-118-1515]).

The history of genetic toxicology demonstrates that only assays that can be adopted by many laboratories and validated through extensive testing are of value for regulatory purposes. Consequently, based on the testing efforts described above, testing schemes were put into law for testing new chemicals ([@b159-ehp-118-1515]), pesticides ([@b158-ehp-118-1515]), and new pharmaceuticals ([@b53-ehp-118-1515]). Recent discussions have explored how new types of assay data might have an impact on the regulation of genotoxic compounds ([@b51-ehp-118-1515]; [@b57-ehp-118-1515]; [@b62-ehp-118-1515]; [@b67-ehp-118-1515], [@b68-ehp-118-1515]; [@b69-ehp-118-1515]; [@b70-ehp-118-1515]; [@b75-ehp-118-1515]; [@b99-ehp-118-1515]; [@b118-ehp-118-1515]; [@b123-ehp-118-1515]; [@b145-ehp-118-1515]). Many such issues will need to be settled before legislation of the type above could ever be instituted for 21st century assays.

Assay flexibility
-----------------

The flexibility of the *Salmonella* assay has allowed the assay to be used in a variety of protocols with a variety of agents, including complex mixtures, gases, and radiation. Current HTS assays use nonvolatile, single agents that are soluble in dimethyl sulfoxide, but agents with other characteristics (e.g., water-soluble compounds, gases) will need to be tested ([@b88-ehp-118-1515]; Tice RR, personal communication). Over the years, this recognition for the *Salmonella* assay resulted in a plethora of modifications that have enabled the assay to be used in an almost infinite variety of ways. These include modifications permitting *a*) the use of small amounts of sample ([@b46-ehp-118-1515]; [@b55-ehp-118-1515]; [@b60-ehp-118-1515]; [@b78-ehp-118-1515]; [@b86-ehp-118-1515]) in semi--high-throughput modes involving colorimetric analysis ([@b87-ehp-118-1515]; [@b156-ehp-118-1515]) and fluorescent assays ([@b13-ehp-118-1515]; [@b27-ehp-118-1515]); *b*) the testing of volatiles and gases ([@b15-ehp-118-1515]; [@b81-ehp-118-1515]); *c*) the testing of body fluids, including urine ([@b28-ehp-118-1515]), feces ([@b41-ehp-118-1515]), breast milk ([@b130-ehp-118-1515]; [@b153-ehp-118-1515]), breast nipple aspirates ([@b95-ehp-118-1515]), and cervical mucus ([@b74-ehp-118-1515]); *d*) the testing of all types of complex mixtures, including air, soil, water, house dust, and combustion emissions (see "Paradigm Shift II" above), and fried meat ([@b96-ehp-118-1515]); *e*) molecular ([@b42-ehp-118-1515]; [@b98-ehp-118-1515]) and genomic analyses ([@b132-ehp-118-1515]; [@b160-ehp-118-1515]); and *f*) the evaluation of mutagenicity inside the International Space Station ([@b136-ehp-118-1515]). This flexibility has permitted the *Salmonella* assay to be used for almost every conceivable type of environmental and molecular epidemiology study.

In addition, numerous modifications of the tester strains or testing conditions have permitted researchers to explore the role of metabolism and to detect the mutagenicity of specific chemical classes of substances ([@b33-ehp-118-1515]; [@b58-ehp-118-1515]; [@b63-ehp-118-1515]; [@b71-ehp-118-1515]; [@b77-ehp-118-1515]; [@b78-ehp-118-1515]; [@b85-ehp-118-1515]; [@b134-ehp-118-1515]; [@b138-ehp-118-1515]; [@b142-ehp-118-1515]; [@b161-ehp-118-1515]). Whether it has been in the development of commercial products ([@b175-ehp-118-1515]), the evaluation of industrial products and wastes ([@b1-ehp-118-1515]; [@b20-ehp-118-1515]; [@b23-ehp-118-1515]; [@b35-ehp-118-1515]; [@b125-ehp-118-1515]), or substances known to contaminate the environment ([@b30-ehp-118-1515]; [@b36-ehp-118-1515]; [@b39-ehp-118-1515]; [@b166-ehp-118-1515]), the *Salmonella* assay has been the screening test of choice in genetic toxicology for nearly four decades. Perhaps a new assay will emerge in the coming years that can assess a comprehensive set of predictive biological changes and also have the range of flexibility exhibited by the *Salmonella* assay.

Standardization of sample preparation
-------------------------------------

The flexibility of the *Salmonella* assay prompted the development of methods to prepare environmental samples for the assay ([@b73-ehp-118-1515]; [@b114-ehp-118-1515]). This included solvents and materials for the delivery of substances to the assay, preparation of environmental and epidemiological samples, and methods for the concentration and determination of doses for testing gases. The coupling of chemical methods with the *Salmonella* assay enabled extensive use of the assay for bioassay-directed chemical fractionation to identify chemical classes of mutagens or individual mutagens ([@b14-ehp-118-1515]; [@b23-ehp-118-1515]; [@b101-ehp-118-1515]; [@b103-ehp-118-1515]; [@b126-ehp-118-1515]), permitting the discovery of many environmental mutagens, such as PBTA (2-phenylbenzotriazole) in surface waters ([@b124-ehp-118-1515]), MX (3-chloro-4-(dichloromethyl)-5-hydroxy-2(5*H*)-furanone) in drinking water ([@b72-ehp-118-1515]), and PhIP (2-amino-1-methyl-6-phenylimidazo\[4,5-*b*\]pyridine) in fried meat ([@b54-ehp-118-1515]). The Tox21 program is already testing herbal agents and has plans to test complex mixtures and environmental samples (Tice RR, personal communication). Coupled with bioassay-directed fractionation, this effort could provide new opportunities for identifying environmental hazards and characterizing health effects from environmental pollution.

Conclusions
===========

If the *Salmonella* assay can be likened to the stethoscope, then ample studies have confirmed repeatedly the invaluable role that the *Salmonella* assay alone plays in identifying rodent ([@b93-ehp-118-1515]; [@b171-ehp-118-1515]; [@b172-ehp-118-1515]) and human ([@b121-ehp-118-1515]) carcinogens. A physician may not make a final diagnosis based solely on the sounds heard through the stethoscope, but in many cases, such sounds prove to be invaluable in formulating the confirmatory procedures. Perhaps some of the emerging HTS ([@b88-ehp-118-1515]), toxicogenomic ([@b52-ehp-118-1515]), and short-term rodent assays ([@b83-ehp-118-1515]) can be likened to the cardiology methods that would be used to follow up anomalies detected by the stethoscope of genetic toxicology, i.e., the *Salmonella* assay.

Because of its historical database, intrinsic value, flexibility, and low cost, the *Salmonella* assay will not soon be replaced for the hazard identification of new chemicals or environmental samples. Indeed, chemicals whose annual production exceeds 1 ton/year (\~ 30,000 compounds) are scheduled to be tested in the *Salmonella* assay under the European Union's Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) legislation ([@b133-ehp-118-1515]). Experience with the *Salmonella* assay should serve as a model for the development and deployment of new approaches to predict and understand the toxicology of substances. The use of the *Salmonella* assay may not be as lasting as that of the stethoscope, but the *Salmonella* assay has made a significant mark on the history of toxicology and has an indispensable role to play in the foreseeable future of 21st century toxicology.
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